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Abstract 
For several decades, hit identification for drug discovery has been facilitated by developments 
in both fragment-based and high-throughput screening technologies. However, a major 
bottleneck in drug discovery projects continues to be the optimization of primary hits from 
screening campaigns to derive lead compounds. Computational chemistry or molecular 
modeling can play an important role during this hit-to-lead (H2L) stage by both suggesting 
putative optimizations and decreasing the number of compounds to be synthesized and 
evaluated. However, it is also crucial to consider the feasibility of organically synthesizing 
these virtually designed compounds. Furthermore, the generated molecules should have 
reasonable physicochemical properties and be medicinally relevant. This review focuses on 
chemistry-driven and structure-based computational methods that can be used to tackle the 
difficult problem of H2L optimization, with emphasis being placed on the strategy developed in 
our laboratory. 
 
Keywords: hit-to-lead optimization; structure-based drug design; de novo design; library 
design; virtual screening 
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1. Introduction 
The first step in a drug discovery project involves the identification of hit compounds that 
typically exhibit weak to moderate affinity for the biological target.[1] These primary hits are 
usually discovered either via the high-throughput screening (HTS) of large collections of 
diverse molecules that are of medium complexity or the use of a fragment-based technology in 
which small chemical libraries of low-molecular-weight fragments are considered.[2] There is a 
current trend toward fragment-based drug discovery (FBDD), since the optimization phase of 
hit compounds from HTS can be fastidious while also maintaining a reasonable molecular 
weight.[3] Moreover, FBDD approaches can cover a larger chemical space in the optimization 
phase, which leads to structural novelty and a higher probability of success. An increasing 
number of success stories have been reported in the past decade, and more than 30 
compounds derived from fragments are currently in clinics or on the market.[4] Following 
orthogonal validation, the confirmed fragments/hits are improved in a subsequent stage called 
hit-to-lead (H2L). 
Typical H2L involves chemical modifications around the validated hit to optimize its affinity for 
the target to become a lead compound.[5] These optimization phases can be completed by 
exploiting a trial-and-error strategy, and several cycles are usually needed to reach a suitable 
affinity. Moreover, other features may be preferred, such as improving the physicochemical 
properties of the compounds and enabling or maintaining a degree of selectivity with respect to 
undesired related targets. In practice, successful H2L optimization can improve the binding 
constants by several orders of magnitude. However, because of the numerous parameters that 
must be considered, the H2L process can also be unsuccessful, time-consuming, and highly 
expensive.[6] 
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Various computer-based approaches have been developed to overcome bottlenecks during 
H2L.[7] For instance, ligand-based methods, such as the Quantitative Structure–Activity 
Relationship (QSAR), can be used to optimize a series of compounds by exploiting available 
experimental data and calculated descriptors.[8] However, this review will focus on 
computational structure-based approaches [9], such as molecular docking, de novo design 
(DnD) and pharmacophore screening. These methods rely on structural data to generate 
models, and success stories have recently been reported.[10] In practice, X-ray crystallography 
is the primary approach to determine the binding mode of a compound in its binding site at the 
atomic level.[11] Such structural data greatly facilitates the H2L optimization by clearly 
identifying nearby protein sub-pockets around the engaged fragment that could be used in the 
optimization phase. 
The most intuitive approach for optimizing a fragment using an in silico structure-based 
approach is the transposition of the growing paradigm from FBDD to the molecular modeling 
context: The affinity of a compound for its target is increased by adding chemical moieties that 
are able to create new favorable contacts while maintaining its original binding mode (Figure 
1A). Two additional H2L strategies used in FBDD, namely, linking and merging, can also be 
virtually mimicked (Figures 1B & 1C).[12] In contrast to the growing concept where a single 
fragment is required, merging and linking consist in the covalent assembly of two non-
overlapping fragments, either directly or via a spacer of variable length.[13] Merging and linking 
strategies are less frequently used than growing and are also more challenging because they 
require two hits and the conservation of their original orientation after their fusion into a single 
compound. However, when these strict criteria are validated, merging and linking can lead to 
outstanding improvements in affinity.[14] In practice, these two approaches are primarily 
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applicable to fragments because merging or linking two compounds with moderate to high 
molecular weight would result in molecules that are too large to be used as probes or drugs. 
Computational-based tools that are able to address growing, linking or merging strategies are 
of primary interest during the H2L stage.[12, 13, 15] For instance, a virtual-focused library that is 
around the validated fragment can be generated within the first step. Subsequently, this library 
can be virtually screened using a constrained docking strategy to mimic the growing paradigm 
and maintain the original interactions. The best putative optimizations are finally selected in the 
top hit list using a scoring function. Alternatively, classical “unconstrained docking” of the 
focused library can be performed. Pharmacophore filters[16] or interaction fingerprints[17] are 
subsequently used to extract putative optimizations that maintain the original binding mode. 
Finally, de novo design algorithms [18, 19], with the binding mode of the validated fragment 
serving as the starting seed, can also be used to sample the cavity and generate putative 
optimized compounds. 
A critical point is determining how to handle the creation of new covalent bonds made during 
the virtual H2L optimization step. A first attempt to generate reasonable structures has been 
made by the RECAP[20] or BRICS[21] methods. For instance, molecules in RECAP are 
fragmented around specific bond types, and new terminal atoms are flagged to capture their 
previous chemical environment. Virtual fragments with complementary flags can subsequently 
be merged to design new virtual compounds. However, there is no assessment regarding their 
synthesis, since neither organic chemistry rules nor the availability of building blocks (BBs) 
were used during the process. This approach leads to either time-consuming follow-up efforts 
to devise synthesis routes or even the inability to produce the virtually generated compounds. 
Consequently, it is of critical importance to address the synthesis tractability of virtually 
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generated compounds in the context of prospective drug discovery projects.[18, 22] In this effort, 
generic reaction schemes “reactants → products” can be encoded to mimic common organic 
synthesis routes.[23, 24] These chemistry rules can subsequently be retained during the design 
of new molecules to facilitate the synthesis stage. 
Several remarkable computational structure-based H2L methods were described in the past 
decade, but they lacked this fundamental requirement of ensuring the synthesizability of the 
generated compounds for use in drug discovery projects.[25, 26] De novo design or alternative 
structure-based H2L methods, which approached this critical issue, are presented in this 
review, with an emphasis on the in silico steps of the DOTS strategy developed in our 
laboratory.[27] 
2. Virtual H2L methods relying on the “de novo design” concept 
By definition, de novo design tools can automatically build compounds “from scratch” within a 
binding site of known 3D structure using predefined sets of substructures and rules governing 
their linkage.[18, 19] In theory, DnD methods enable the exploration of a considerably larger 
chemical space, which is in contrast to classic virtual screening (VS), where only commercially 
available compounds are tested. Although conceptually similar, DnD tools can be distinguished 
by their algorithms, ranking/scoring functions, convergence criteria, and branch-pruning 
strategies. This methodological approach, developed in the early 1990s, was initially appealing 
but is currently not widely practiced by chemoinformaticians.[28, 29] Indeed, DnD methods often 
exhibit several critical drawbacks that limit their application to prospective cases. The primary 
drawbacks include the following: 1) low reliability in predicting affinity, 2) potentially poor 
physicochemical properties of the designed compounds and, most importantly, 3) issues 
regarding the compounds’ synthetic tractability.[18] 
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As a response to the first criticism, in silico H2L methods that rely on DnD approaches, as 
introduced below, were upgraded to use a pre-positioned fragment in the binding site as the 
original seed. Starting from an experimentally validated fragment with a known binding mode is 
likely to increase the reliability of their predictions.  
The third criticism of DnD approaches - the major drawback - concerns the difficulty in 
synthesizing certain of the suggested compounds because the rules governing bond creation 
during the process did not take into account any organic chemistry knowledge. This primary 
issue was approached by incorporating virtual reaction schemes in the workflow to ensure the 
synthetic accessibility with more confidence. Both ligand-based and structure-based DnD tools 
were developed to address this problem. DOGS[24] and SYNOPSIS[30] are popular examples of 
such chemistry-driven ligand-based DnD methods. However, other structure-based DnD 
approaches that rely on both substructure seed prepositioned in the binding site and encoded 
chemistry knowledge exist and are discussed below. 
The SPROUT program was one of the first published DnD software in the 1990s, but several 
major upgrades have been recently added.[29] This program is now able to take a validated hit 
or fragment as seed and to incorporate chemistry-based rules during the virtual design 
process. SPROUT was successfully used to design inhibitors of dihydroorotate dehydrogenase 
enzyme[31], and more recently BACE-1 inhibitors, based on a synthetic Suzuki reaction 
scheme.[32] 
LigBuilder[33] is another validated tool that was recently updated to tackle the usual drawbacks 
from DnD software. The current version (2.0), is able to perform both ab initio design and lead 
optimization of a compound of interest while considering both synthesis accessibility and filter-
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based drug-likeness of the designed compounds.[34] LigBuilder was successfully applied to 
generate nanomolar inhibitors of Cyclophilin A.[35] 
Similarly, the AutoGrow tool[36] was also updated to include organic chemistry rules within the 
operators of its evolutionary-based algorithm.[37] In this instance, the popular Autodock Vina 
docking engine is used for both conformational sampling and scoring stages.[38] 
Physicochemical filters were also added to reject non drug-like compounds. 
Beccari et al developed a suite of programs called LiGen for DnD that both handles the 
chemical rules for designing accessible compounds and efficient docking with pharmacophore 
constraints.[39] Each module can be used either separately or combined in a complex workflow 
procedure. This toolbox is reported to tackle most issues in the DnD field while being efficient 
from a computational point of view. However, there is no case study to highlight its ability in 
either retrospective or prospective cases. 
Cheron et al reported the development of OpenGrowth for the computer-based H2L 
optimization of compounds under binding site constraints.[40] In this study, the probability that a 
given fragment is connected to another one in a reference drug dataset is used to guide the 
design process. At the end of the process, designed molecules exhibit both reasonable 
synthetic accessibility and good physicochemical properties, although organic synthesis routes 
are not explicitly taken into account. A new version, including the implementation of an explicit 
synthetic accessibility score during the design process, is planned. 
It should be noted that many DnD tools were only validated in retrospective case studies. 
However, all these programs exhibit promise and should be useful for prospective projects 
aiming to design active and accessible compounds. 
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3. Alternative approaches for in silico H2L optimization 
Chevillard et al optimized several fragment-like compounds into low micromolar ligands for the 
β2-adrenergic receptor target.[41] The PINGUI method relies on both structural data and a 
series of 58 encoded organic chemistry rules published by Hartenfeller et al for designing 
putative accessible ligands by merging an original fragment with compatible BBs.[23] In 
practice, the SEED program is used to dock pre-processed BBs (called surrogates) where the 
reactive center is modified according to the considered synthesis reaction.[42] For instance, a 
methylamine group will replace the aldehyde function from the BB if the reductive amination 
synthesis scheme is selected. In a second step, putatively interesting surrogates, where the 
reactive center is sufficiently close to the one from the original hit without any overlap with 
other atoms, are identified. Next, final products corresponding to the coupling of the hit and 
selected surrogates are generated and docked using the DOCK software.[43] A last modeling 
step involving the refinement and rescoring of selected poses using the SZYBKI method is 
performed.[44] 
The LeadOp+R method was developed to perform structure-based H2L optimization with 
synthetic accessibility.[45] This method relies on approximately 200 encoded chemical reactions 
while allowing multi-steps design. The pipeline starts with a query structure pre-positioned in 
the binding site and user-defined preferred ligand-receptor interactions. New 1D/2D 
compounds are created by combining the current structure with BBs by using encoded 
chemistry rules without knowledge of the binding site at this stage. 3D conformers are 
subsequently generated for each compound, superimposed to the shared reference 
substructure in the binding site, and evaluated for their ability to make additional favorable 
contacts without any clashes. The cycle stops when required interactions between both entities 
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are fulfilled. Several physicochemical filters are used to discard compounds with undesirable 
properties. They successfully applied their approach on two retrospective projects: several 
known potent inhibitors were designed for each target, while suggested synthetic routes 
shared steps with published ones. 
An original strategy, relying on both pharmacophore and docking concepts, allowed Schulz et 
al to discover several covalent inhibitors of the enteroviral 3C protease target.[46] First, a new 
pharmacophore feature type in the LigandScout software was developed to look for 
predefined reactive functions in the vicinity of a cysteine residue.[47] Next, a 3D-pharmacophore 
was designed to catch fundamental interactions with the enteroviral 3C protease while looking 
for covalent binders using this new feature. Then, a library of fragment-like compounds was 
screened against the 3D-pharmacophore. Several fragment hits were identified and 
experimentally validated using mass spectrometry. The best one was further investigated but 
exhibited some instability. To bypass this issue, a scaffold hopping strategy, using simple 
SMARTS-based substructure search, was successfully employed to find alternative binding 
cores that still contain the required features. A protocol was later developed for the rational 
design of optimized analogs of the best new hit, while maintaining the fundamental interactions 
with the protein. Thus, a virtual library was generated by coupling the hit and commercially 
available BBs using encoded chemistry reaction rules. LigandScout and GOLD programs were 
used to identify putative optimizations that would occupy adjacent sub-pockets. Finally, the 
authors reported both reversible and irreversible inhibitors of the enteroviral 3C protease 
target. 
Evers et al from the Sanofi-Aventis company reported the CROSS method for either 
rescaffolding or the optimization of compounds using explicit handling of organic reactions.[48] 
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The CROSS approach relies on the BROOD software to quickly identify pre-processed 
fragments that could replace an undesirable core by using “exit vectors” and 3D-shape 
analysis.[49] The main advantage is that these pre-processed fragments are directly connected 
to available BBs and specific chemical reactions for easier continued investigation. In addition, 
the use of chemical protection groups is also allowed to facilitate the results in the synthesis 
steps. Finally, generated compounds are post-processed using molecular docking and ADME-
Tox predictions. While the main usage is rescaffolding, the CROSS method can also be 
employed in virtual H2L optimization using either a growing or linking strategy. Indeed, linking 
and rescaffolding are similar concepts, where a linker is selected to connect two moieties while 
maintaining their original orientation. 
AutoCouple was recently reported as a useful tool to expand the chemical space in hit 
optimization.[50] In the first step, a diversity-oriented library is designed by virtually coupling one 
hit that includes a reactive function, with a list of commercially available BBs using encoded 
chemistry rules. In a second step, the rDock program is used to screen the library while adding 
constraints on the original moiety to maintain the reference binding mode during the 
conformational sampling stage.[51] The authors applied this strategy to the design of potent 
CBP bromodomain inhibitors. An acetyl benzene moiety served as the reference substructure 
able to mimic the acetylated lysine from histone tails, which are recognized by this epigenetic 
reader. Different organic reactions were considered to build the virtual library that was docked 
by rDock in the CBP binding site with constraints on the reference moiety. The best poses 
were minimized using the CHARMM molecular mechanic program[52] during a post-processing 
stage, before the final selection of target compounds to be synthesized was made. This study 
led to the discovery of several nanomolar inhibitors for the CBP target. The predicted binding 
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mode of several compounds was successfully confirmed by solving the structure of the 
complex using X-ray crystallography. 
Finally, the Diversity-Oriented Target-focused Synthesis (DOTS) is an integrated strategy 
developed in our laboratory for generic H2L optimization relying on the growing paradigm.[27] 
This strategy involves molecular modeling (chemical library design and structure-based VS) 
and robotic-based experimental stages (diversity-oriented de novo synthesis and in vitro 
evaluation and validation). The virtual steps are an upgrade from a former computational 
optimization method[26] relying on the RECAP algorithm[20], which did not consider the synthetic 
accessibility of the designed compounds. The general DOTS workflow can be summarized as 
follows (Figure 2): 1) hit identification and characterization of its binding mode using structural 
biophysics method, such as X-ray crystallography; 2) design of a virtual focused library around 
the hit using a database of commercially available BBs, encoded organic chemical rules, and 
post-processing of the library to extract a diverse subset of representative compounds that also 
possess reasonable physicochemical properties without any undesirable functions to medicinal 
chemists; 3) constrained VS of the library with the S4MPLE tool[26, 53] to identify the best 
putative optimizations that create additional favorable contacts while maintaining the original 
binding mode; 4) parallel synthesis of the compounds using a chemistry robot; and 5) in vitro 
evaluation with a robotic screening workstation. The in silico part of DOTS relies on real 
chemical knowledge and allows for the production of theoretically accessible and diverse 
compounds, while exploring the chemical space around the hit, and matching regular 
physicochemical and medicinal chemistry-like features. The DOTS strategy was successfully 
applied to the optimization of a previously reported xanthine core that binds the first 
bromodomain (BD1) of the BRD4 protein.[54] Several sub-micromolar inhibitors were developed 
and validated in one cycle of optimization, with the best one displaying a Kd value of 190 nM. 
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X-ray crystallography was used to solve the structure of the best inhibitor in complex with the 
BRD4(BD1) protein, and confirmed the predicted binding mode. Several features, including 
linking optimization and design of covalent inhibitors, are currently under development in order 
to address all available H2L strategies. 
4. Summary and Outlook section 
This review contributes to an overview of structure-based computational H2L methods that 
tackle the synthetic accessibility of virtually generated compounds. The different programs 
discussed in this review, and their main characteristics, are summarized in Table 1. Most of 
them currently encode real chemistry knowledge to design molecules that can be synthesized 
with high probability in one or two steps. Such approaches help scientists design accessible 
and optimized compounds that perfectly fit the binding site of the target. 
Despite the shared ability to handle virtual chemistry, these in silico structure-based H2L 
methods rely on various strategies. De novo design algorithms start from a given compound as 
the original seed to perform the optimization process, while alternative approaches use 
docking or pharmacophore concepts to identify promising compounds from a virtual focused 
library that was designed around the hit to optimize. 
In certain cases, a single reaction scheme is considered, but it is still possible to explore a 
large chemical space around the starting hit due to the high number of commercially available 
BBs. Moreover, target compounds selected using these approaches can also be produced in 
parallel using robotic platforms when a single reaction is considered, as exemplified in the 
DOTS approach. 
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Computational H2L can be useful to optimize hits in a time-efficient and cost-effective manner, 
as highlighted by successful cases described in this review. These in silico methods clearly 
should play a larger role in drug discovery in both academic and pharmaceutical environments. 
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Figure legends 
 
Figure 1. Selected examples of fragment growing, linking and merging strategies. 2D 
structure, 3D ligand-protein complex (with PDB code) and binding constants (IC50 or AC50) are 
provided for each fragment and optimized compound. Small organic compounds are displayed 
in ball-and-stick representation. Fragments are displayed in pink and optimized compounds are 
shown in cyan. Direct hydrogen bonds between optimized ligands and protein are represented 
by green dashed lines. A. Growing example for the development of Phosphodiesterase (PDE) 
inhibitors.[55] B. Linking example leading to the discovery of a Pyruvate kinase (PKM2) 
activator.[56] C. Merging example towards the development of small molecule inhibitors of 
Mycobacterium tuberculosis transcriptional repressor protein (EthR).[57] 
 
Figure 2. Schematic workflow of the DOTS strategy. 1) Following hit identification, the 
binding mode is characterized using structural biophysics methods such as X-ray 
crystallography. 2) A virtual focused library is conceived by combining a database of 
functionalized BBs with an activated form of the original hit using SMARTS-encoded medicinal 
chemistry-relevant organic synthesis rules. The raw library is then filtered to extract a diverse 
set of compounds with reasonable physicochemical properties. 3) The focused library is 
virtually screened under constraints with S4MPLE to identify compounds that create additional 
favorable contacts while maintaining the original binding mode. 4) The selected compounds 
are synthesized using an automated parallel chemistry robot. 5) Compounds are finally 
evaluated in vitro with a robotic screening workstation and the best molecules are further 
validated using orthogonal methods.  
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